Loading the session
Loading the session
Loading instrument
$390.20
+0.40%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −8.7% (SPY −2.6%, XLV +9.9%). 3 months: +41.2% (SPY −2.2%, XLV +13.5%). 1 year: +96.1% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NTRA, SPY and XLV · as of 3 Nov 2026
3 Nov 2026 volume of 3.9M shares was 2.3× the average of the 30 sessions before it (1.7M), as the price rose 2.6%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
The 3 Nov 2026 close of $388.63 was 2.5% above its 50-day average ($379.22) and 45.2% above its 200-day average ($267.62). It has closed above the 200-day for 112 sessions, since 27 May 2026. The 50-day average crossed above the 200-day on 4 Jun 2026, 105 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Closed at $388.63 on 3 Nov 2026: 11.2% below the 52-week high of $437.41 (6 Oct 2026) and 114.7% above the low of $181.00 (27 Mar 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
5.9M shares were sold short at the 15 Oct 2026 settlement, 4.1% of the 144.1M shares outstanding; covering them would take 3.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 3 Nov 2026 close
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
August 7, 2026
+21.37%November 13, 2024
+19.13%March 9, 2022
−32.79%